proe-PAFF-e-nown 
Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CNS: dizziness, shaking, weakness.
EENT: blurred vision.
CV: SUPRAVENTRICULAR ARRHYTHMIA, VENTRICULAR ARRHYTHMIAS, conduction disturbances, angina, bradycardia, hypotension.
GI: altered taste, constipation, nausea, vomiting, diarrhea, dry mouth.
Hemat: AGRANULOCYTOSIS.
Derm: rash.
MS: joint pain.
Drug-Drug:
Drug-Food:
(Generic available)
Absorption: Although well absorbed following oral administration, undergoes rapid hepatic metabolism (bioavailability 3–11%).
Distribution: Widely distributed; crosses the placenta.
Metabolism/Excretion: Extensively metabolized by the liver (CYP1A2, CYP2D6, and CYP3A4 enzyme systems; the CYP2D6 enzyme system exhibits genetic polymorphism), some metabolites have antiarrhythmic activity. 7% of population may be poor metabolizers and may have significantly ↑ propafenone concentrations and an ↑ risk of adverse effects.
Half-life: 2–10 hr in extensive metabolizers, 10–32 hr in slow metabolizers.
NDC Code*